Avacta Expands its Pipeline with Two Novel Assets Developed Using its pre|CISION® Platform
Avacta Group PLC (AIM:AVCT) Avacta appoints Chief Scientific Officer
Avacta Group strengthens executive team with appointment of Michelle Morrow, PhD as Chief Scientific Officer.
Avacta Group PLC – Avacta Unveils Pipeline Expansion at EORTC 2024
Avacta to Unveil Pipeline Expansion and Novel, Next-Generational Targeted Cancer Therapy Programs at 2024 EORTC-NCI-AACR Symposium
Avacta Group PLC – Avacta to present clinical data at ESMO Congress
Avacta to present updated clinical data on AVA6000 at the European Society for Medical Oncology (ESMO) Congress
Avacta Group PLC (AIM:AVCT) Update on Convertible Bond Payment
Avacta Group plc (AIM: AVCT), a clinical stage life sciences company developing innovative, targeted cancer treatments and powerful diagnostics today announces that it has elected to settle in cash the
Avacta Group plc (AIM: AVCT) AGM Business Update
AGM Business Update Second Cohort in the AVA6000 Phase 1 Arm 2 Completed, Patient Dosing is Ongoing in Cohort Three Avacta Announces the Assembly of a Scientific Advisory Board to
Avacta Group PLC (AIM:AVCT) Successful Completion of First Cohort
Successful Completion of First Cohort and Dosing of Three Patients of the Second Cohort in Arm 2 of Avacta’s AVA6000 Phase 1 trial Initiation of FAPI-PET Sub-study in the
Avacta Group PLC (AIM:AVCT) AVA6000 Abstract Release by AACR and Full Presentation Update
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, today announces that the abstract of the poster to be presented at the
Avacta Group PLC (AIM:AVCT) Update on AVA6000 Phase 1a Clinical Trial Progress
Three patients now dosed in the US in two-weekly dose escalation study Avacta receives approval to enrol patients in the UK in the ongoing two-weekly dose escalation study
Avacta Group PLC (AIM:AVCT) Result of Placing
Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and diagnostics, is pleased to announce that, further to its announcement on 28 February 2024, the Company has successfully
Avacta Group PLC (AIM:AVCT) Appointment of Christina Coughlin
Appointment of Christina Coughlin, M.D., Ph.D. as Head of Research and Development
Avacta Group PLC (AIM:AVCT) Appointment of Chief Business Officer
Appointment signals commercial emphasis for Avacta to leverage clinical progress